Compound News and Research

RSS

Panacea Pharmaceuticals selects Goodwin to complete novel vaccine Fill / Finish project

Goodwin Biotechnology, Inc., a biological Contract Development and Manufacturing Organization that specializes in bioprocess development and GMP manufacturing of biopharmaceuticals utilizing Mammalian Cell Culture expression systems and Bioconjugation technologies, was selected by Panacea Pharmaceuticals, Inc. to complete a novel Fill / Finish project, as well as Quality Control release and stability testing for a therapeutic, nanoparticle cancer vaccine based on the Human Aspartyl (Asparaginyl) β-Hydroxylase (HAAH) tumor-specific protein to support Phase I clinical trials in patients with various solid tumor cancers.

11 May 2015

Overview of Blueprint Medicines' kinase drug discovery strategy published in JCI

Blueprint Medicines today announced that the Journal of Clinical Investigation published an overview of the Company's kinase drug discovery and development strategy. The publication underscores Blueprint Medicines' focus on identifying novel genomically defined disease drivers and the use of novel chemistry from its proprietary compound library to craft highly selective kinase inhibitors for new and difficult-to-drug kinase targets.

11 May 2015

New compound offers longer lasting painkilling effects

Medications have long been used to treat pain caused by injury or chronic conditions. Unfortunately, most are short-term fixes or cause side effects that limit their use. Researchers at the University of Missouri have discovered a new compound that offers longer lasting painkilling effects, and shows promise as an alternative to current anesthetics.

7 May 2015

Cardiff scientists develop novel anti-cancer stem cell compound

Cardiff University scientists have developed a novel anti-cancer stem cell agent capable of targeting aggressive tumour forming cells common to breast, pancreas, colon and prostate cancers.

7 May 2015

Scientists uncover new pharmaceutical strategy for treating melanoma

Scientists looking to better understand the mechanisms behind the origin and spread of melanoma tumors have uncovered a possible role for a decades-old antibacterial agent in treating these aggressive and increasingly common cancers.

6 May 2015

Scientists identify mechanism that explains how some stem cells get new identity

Scientists at the University of Copenhagen have identified one mechanism that explains how some stem cells choose to become a given cell type: the cells combine specific sets of proteins at precise positions along the DNA. When these particular groups of proteins are combined, the gates are opened so that certain groups of genes can now be used, giving the cells a new identity.

6 May 2015

Johns Hopkins researchers develop new strategies to treat depression in children, adolescents

A multidisciplinary team of Johns Hopkins researchers has developed two new strategies to treat depression in young people using the selective serotonin reuptake inhibitor (SSRI) class of medications. These strategies, published May 5 in the journal Translational Psychiatry, incorporate a new understanding of how to mitigate the risk of suicide while on SSRI treatment.

6 May 2015

Green tea compound, voluntary exercise slow Alzheimer's disease progression in mice

According to the National Institutes of Health, Alzheimer's disease (AD) may affect as many as 5.5 million Americans. Scientists currently are seeking treatments and therapies found in common foods that will help stave off the disease or prevent it completely.

5 May 2015

Researchers identify multiple types of resistance to new targeted lung cancer drug

After identifying three different types of resistance to a promising investigational lung cancer drug in a phase 1 trial, a team of researchers led by Dana-Farber Cancer Institute scientists say new targeted inhibitors and combinations are urgently needed to stay ahead of tumors' constant and varied molecular shape-shifting.

5 May 2015

Makindus' MI-100 granted EMA orphan drug designation for treatment of Stargardt's Disease

Makindus, Inc. a specialty pharmaceutical development company focused on ophthalmology announced today that the European Medicines Agency has granted orphan drug designation for their lead candidate, MI-100, for the treatment of Stargardt's Disease.

4 May 2015

Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2015. For the first quarter of 2015, the Company reported a net loss of $1.2 million, or $0.01 loss per share, compared to a net loss of $11.8 million, or $0.17 loss per share, for the same period in 2014.

30 Apr 2015

OncoGenex provides update on Phase 3 ENSPIRIT trial evaluating custirsen for treatment of NSCLC

OncoGenex Pharmaceuticals, Inc. announced today it has filed an amendment with the U.S. Food and Drug Administration, as well as initiated filing with regulatory agencies in other countries, to amend the statistical design and analysis plan of its pivotal, international Phase 3 ENSPIRIT trial evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC).

30 Apr 2015

Promising compound blocks production of beta amyloid peptides in Alzheimer's mouse model

Offering a potential early intervention for Alzheimer's disease (AD), researchers at University of California, San Diego School of Medicine and Cenna Biosciences, Inc. have identified compounds that block the production of beta amyloid peptides in mice.

30 Apr 2015

Research provides insights into the ability of FL118 to overcome treatment resistance

The latest research from the team that discovered the novel anticancer agent FL118 highlights distinctive characteristics of this small-molecule compound and provides insights into its ability to overcome the persistent problem of treatment resistance. In findings reported in Molecular Cancer, Fengzhi Li, PhD, of Roswell Park Cancer Institute, and colleagues provide new evidence that FL118 may be more effective than two structurally similar injectable drugs and, additionally, may be effective as an oral agent.

30 Apr 2015

US Liquid Handling Market estimated to reach $974 million in 2021

The trend of laboratories moving from manual methods to automated workflows is advancing momentum in the uptake of liquid handling instruments in the U.S. Stricter regulations and a growing focus on data precision, efficiency and reproducibility are driving the transition to automation in liquid handling.

29 Apr 2015

Researchers discover key mechanism in neural death that causes Parkinson's disease

In studying the molecular biology of brain development, a team of researchers led by Ludwig Stockholm director Thomas Perlmann has discovered how disruption of a developmental mechanism alters the very nerve cells that are most affected in Parkinson's disease.

29 Apr 2015

SLU selected to work on universal flu vaccine project

Supported by a federal contract, Saint Louis University will study a concept for a universal flu vaccine that is designed to protect people from influenza pandemics that could turn deadly as well as seasonal flu caused by the influenza A virus.

29 Apr 2015

TAXIS Pharmaceuticals' TXA709 compound shows promise in combating antibiotic resistance

TAXIS Pharmaceuticals, a drug-discovery company focused on developing a new class of antibiotic agents to treat life-threatening, multidrug-resistant bacterial infections, today announced the presentation of data demonstrating the promise of its lead clinical candidate, TXA709, in combating antibiotic resistance.

27 Apr 2015

OncoGenex terminates agreement with Teva, regains rights to custirsen

OncoGenex Pharmaceuticals, Inc. today announced that its wholly owned subsidiary, OncoGenex Technologies Inc., executed a termination agreement with Teva Pharmaceuticals Ltd. under which OncoGenex will regain rights to custirsen, an investigational compound currently in Phase 3 clinical development as a treatment for prostate and lung cancers.

27 Apr 2015

Porvair Previews New Microplate Products at ACHEMA

Visitors to ACHEMA 2015 have been invited by Porvair Sciences to Stand F44 in Halle 4.2 to see their expansive range of application optimised microplates and microplate equipment...

From Porvair Sciences Limited 24 Apr 2015

Compound News and Research

Panacea Pharmaceuticals selects Goodwin to complete novel vaccine Fill / Finish project

Overview of Blueprint Medicines' kinase drug discovery strategy published in JCI

New compound offers longer lasting painkilling effects

Cardiff scientists develop novel anti-cancer stem cell compound

Scientists uncover new pharmaceutical strategy for treating melanoma

Scientists identify mechanism that explains how some stem cells get new identity

Johns Hopkins researchers develop new strategies to treat depression in children, adolescents

Green tea compound, voluntary exercise slow Alzheimer's disease progression in mice

Researchers identify multiple types of resistance to new targeted lung cancer drug

Makindus' MI-100 granted EMA orphan drug designation for treatment of Stargardt's Disease

Neurocrine reports net loss of $1.2 million for first quarter 2015

OncoGenex provides update on Phase 3 ENSPIRIT trial evaluating custirsen for treatment of NSCLC

Promising compound blocks production of beta amyloid peptides in Alzheimer's mouse model

Research provides insights into the ability of FL118 to overcome treatment resistance

US Liquid Handling Market estimated to reach $974 million in 2021

Researchers discover key mechanism in neural death that causes Parkinson's disease

SLU selected to work on universal flu vaccine project

TAXIS Pharmaceuticals' TXA709 compound shows promise in combating antibiotic resistance

OncoGenex terminates agreement with Teva, regains rights to custirsen

Porvair Previews New Microplate Products at ACHEMA

Advancing therapeutic biopolymer development eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News